Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year

PR Newswire
Tuesday, January 31, 2023 at 9:05pm UTC

Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year

PR Newswire

Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related 
Practices and Policies

REDWOOD CITY, Calif., Jan. 31, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2023 Bloomberg Gender-Equality Index (GEI) for the second consecutive year. The GEI is a modified, market capitalization-weighted index developed to gauge the performance of public companies dedicated to reporting gender-related data. This reference index measures gender equality across five pillars: leadership & talent pipeline, equal pay & gender pay parity, inclusive culture, anti-sexual harassment policies and external brand.

"Our inclusion in this year's GEI is a reflection of our continued commitment to fostering a diverse and more inclusive work culture in which all employees can thrive," said Lori Ciano, Chief Human Resources Officer of Nevro. "With women comprising over 50% of our global workforce, fostering gender equality continues to be a top priority for our company. We're thrilled to be recognized for our commitment to nurturing diverse talent, cultivating an inclusive culture and setting a market standard for disclosing efforts to address gender inequality."

Nevro submitted a social survey created by Bloomberg, in collaboration with subject matter experts globally. Those included on this year's index scored at or above a global threshold established by Bloomberg to reflect disclosure and the achievement or adoption of best-in-class statistics and policies.

The 2023 GEI included 484 companies across 45 countries and regions. For more information on the GEI visit:

Learn more about Nevro's culture and diversity & inclusion efforts

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. 

Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | 


Cision View original content to download multimedia:

SOURCE Nevro Corp.